Pauline Verdijk

Pauline Verdijk

Auto-generated profile, based on publicly available information

Pauline Verdijk

Institute for Translational Vaccinology (Intravacc), Bilthoven, The Netherlands

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 October 2005 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
IVI Jolanda M de Vries
I Jolanda M de Vries
WLW Joost Lesterhuis
W Joost Lesterhuis
JBJelle O Barentsz
Jelle O Barentsz
PVPauline Verdijk
Pauline Verdijk
JKJ Han van Krieken
J Han van Krieken
CFCarl Figdor
Carl Figdor

1 January 2001 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
JKJan H. Kessler
Jan H. Kessler
NBNico J. Beekman
Nico J. Beekman
SBSandra A. Bres-Vloemans
Sandra A. Bres-Vloemans
PVPauline Verdijk
Pauline Verdijk
PVPeter A. van Veelen
Peter A. van Veelen
CMCornelis J.M. Melief
Cornelis J.M. Melief
We report the efficient identification of four human histocompatibility leukocyte antigen (HLA)-A*0201–presented cytotoxic T lymphocyte (CTL) epitopes in the tumor-associated antigen PRAME using an improved “reverse immunology” strategy. Next to motif-based HLA-A*0201 binding prediction and actual binding and stability assays, analysis of in vitro proteasome-mediated digestions of polypeptides encompassing candidate epitopes was incorporated in the epitope prediction procedure. Proteasome cleavage pattern analysis, in particular determination of correct COOH-terminal cleavage of the putative epitope, allows a far more accurate and selective prediction of CTL epitopes. Only 4 of 19 high affinity HLA-A*0201 binding peptides (21%) were found to be efficiently generated by the proteasome in vitro. This approach avoids laborious CTL response inductions against high affinity binding peptides that are not processed and limits the number of peptides to be assayed for binding. CTL clones induced against the four identified epitopes (VLDGLDVLL, PRA100–108; SLYSFPEPEA, PRA142–151; ALYVDSLFFL, PRA300–309; and SLLQHLIGL, PRA425–433) lysed melanoma, renal cell carcinoma, lung carcinoma, and mammary carcinoma cell lines expressing PRAME and HLA-A*0201. This indicates that these epitopes are expressed on cancer cells of diverse histologic origin, making them attractive targets for immunotherapy of cancer.

1 April 2009 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
PVPauline Verdijk
Pauline Verdijk
EAErik Aarntzen
Erik Aarntzen
WLW. Joost Lesterhuis
W. Joost Lesterhuis
ABA.C. Inge Boullart
A.C. Inge Boullart
EKEllemieke Kok
Ellemieke Kok
IVI. Jolanda M. De Vries
I. Jolanda M. De Vries
Purpose: The success of immunotherapy with dendritic cells (DC) to treat cancer is dependent on effective migration to the lymph nodes and subsequent activation of antigen-specific T cells. In this study, we investigated the fate of DC after intradermal (i.d.) or intranodal (i.n.) administration and the consequences for the immune activating potential of DC vaccines in melanoma patients.

15 September 2003 in Blood
Verified
Journal Article
Open access
PDF file
MSMartine J. Smit
Martine J. Smit
PVPauline Verdijk
Pauline Verdijk
ERElisabeth M. H. van der Raaij-Helmer
Elisabeth M. H. van der Raaij-Helmer
MNMarjon Navis
Marjon Navis
PHPaul Hensbergen
Paul Hensbergen
CTCornelis P. Tensen
Cornelis P. Tensen
The chemokines CXCL9, 10, and 11 exert their action via CXC chemokine receptor-3 (CXCR3), a receptor highly expressed on activated T cells. These interferon γ (IFNγ)–induced chemokines are thought to be crucial in directing activated T cells to sites of inflammation. As such, they play an important role in several chronic inflammatory diseases including ulcerative colitis, multiple sclerosis, artherosclerosis, and delayed-type hypersensitivity reactions of the skin. In this study, we first demonstrate that in COS-7 cells heterologously expressing CXCR3, CXCL11 is a potent activator of the pertussis toxin (PTX)–sensitive p44/p42 mitogen-activated protein kinase (MAPK) and Akt/phosphatidylinositol 3 kinase (PI3K) pathways. Next, we show that these signal transduction pathways are also operative and PTX sensitive in primary human T cells expressing CXCR3. Importantly, abrogation of these signaling cascades by specific inhibitors did not block the migration of T cells toward CXCR3 ligands, suggesting that MAPK and Akt activation is not crucial for CXCR3-mediated chemotaxis of T cells. Finally, we demonstrate that CXCR3-targeting chemokines control T-cell migration via PTX-sensitive, phospholipase C pathways and phosphatidylinositol kinases other than class I PI3Kγ.

6 March 2008 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Open access
PDF file
ABA. C. Inge Boullart
A. C. Inge Boullart
EAErik H. J. G. Aarntzen
Erik H. J. G. Aarntzen
PVPauline Verdijk
Pauline Verdijk
JJJoannes F. M. Jacobs
Joannes F. M. Jacobs
DSDanita H. Schuurhuis
Danita H. Schuurhuis
IVI. Jolanda M. De Vries
I. Jolanda M. De Vries
Dendritic cells (DC) are professional antigen-presenting cells of the immune system that play a key role in regulating T cell-based immunity. In vivo, the capacity of DC to activate T cells depends on their ability to migrate to the T cell areas of lymph nodes as well as on their maturation state. Depending on their cytokine-secreting profile, DC are able to skew the immune response in a specific direction. In particular, IL-12p70 producing DC drive T cells towards a T helper 1 type response. A serious disadvantage of current clinical grade ex vivo generated monocyte-derived DC is the poor IL-12p70 production. We have investigated the effects of Toll-like receptor (TLR)-mediated maturation on ex vivo generated human monocyte-derived DC. We demonstrate that in contrast to cytokine-matured DC, DC matured with poly(I:C) (TLR3 ligand) and/or R848 (TLR7/8 ligand) are able to produce vast amounts of IL-12p70, but exhibit a reduced migratory capacity. The addition of prostaglandin E2 (PGE2) improved the migratory capacity of TLR-ligand matured DC while maintaining their IL-12p70 production upon T cell encounter. We propose a novel clinical grade maturation protocol in which TLR ligands poly(I:C) and R848 are combined with PGE2 to generate DC with both high migratory capacity and IL-12p70 production upon T cell encounter.

19 December 2003 in European Journal of Immunology
Verified
Journal Article
Open access
PDF file
PVPauline Verdijk
Pauline Verdijk
PVPeter A. van Veelen
Peter A. van Veelen
ARArnoud H. de Ru
Arnoud H. de Ru
PHPaul Hensbergen
Paul Hensbergen
KMKensaku Mizuno
Kensaku Mizuno
AMA. Mieke Mommaas
A. Mieke Mommaas
Upon activation, tissue residing immature dendritic cells (DC) start to migrate towards the draining lymph node and mature into efficient antigen‐presenting cells. During maturation DC loose their capacity to endocytose antigens, change their surface expression of adhesion molecules, chemokine receptors, and costimulatory molecules, and change morphology. We employed 2D‐PAGE and mass spectrometry to identify additional differentially expressed proteins in immature and mature DC. Human monocyte‐derived DC were matured with LPS and protein expression profiles were compared before andafter maturation. One of the proteins differentially expressed between immature and mature DC was identified as the actin‐binding protein cofilin. We show here that cofilin is dephosphorylated in response to several maturation stimuli (i.e. CD40 ligand, LPS or a combination of TNF‐α and prostaglandin E2). Moreover, dephosphorylated cofilin translocated towards the plasmamembrane during maturation. Importantly, this correlated with an increase in filamentous actin and the appearance of veils, suggesting a role for cofilin in cytoskeletal rearrangements during maturation.